LCD for Bladder Tumor Antigen (L1303)

 

Contractor Information

Contractor Name 

BlueCross BlueShield of Tennessee (Riverbend Government Benefits Administrator) 

Contractor Number 

00390 

Contractor Type 

FI 

 

LCD Information

LCD ID Number 

L1303 

 

LCD Title 

Bladder Tumor Antigen 

 

Contractor's Determination Number 

1303 

 

AMA CPT / ADA CDT Copyright Statement 

CPT codes, descriptions and other data only are copyright 2007 American Medical Association (or such other date of publication of CPT). All Rights Reserved. Applicable FARS/DFARS Clauses Apply. Current Dental Terminology, (CDT) (including procedure codes, nomenclature, descriptors and other data contained therein) is copyright by the American Dental Association. © 2002, 2004 American Dental Association. All rights reserved. Applicable FARS/DFARS apply.  

 

CMS National Coverage Policy 

Title XVIII of the Social Security Act, Section 1862(a)(1)(A). This section excludes coverage for items or services that are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

Title XVIII of the Social Security Act, Section 1862 (a)(7). This section prohibits Medicare payment for any expenses on items and services incurred for routine physical examinations.

Title XVIII of the Social Security Act, Section 1833 (e). This section prohibits Medicare payment for any claim that lacks the necessary information to process the claim.
 

 

Primary Geographic Jurisdiction 

New Jersey
Tennessee
 

 

Secondary Geographic Jurisdiction 

Alaska
Alabama
Arkansas
Arizona
California
Colorado
Connecticut
Florida
Georgia
Hawaii
Iowa
Idaho
Illinois
Indiana
Kansas
Kentucky
Louisiana
Massachusetts
Maryland
Maine
Michigan
Minnesota
Missouri
Mississippi
North Carolina
North Dakota
Nebraska
New Jersey
New Mexico
Nevada
New York
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
Tennessee
Texas
Utah
Virginia
Vermont
Washington
Wisconsin
West Virginia
Wyoming
 

 

Oversight Region 

Region IV
 

 

 

Original Determination Effective Date 

For services performed on or after 07/01/1997  

 

Original Determination Ending Date 

 

 

Revision Effective Date 

For services performed on or after 12/08/2005  

 

Revision Ending Date 

 

 

Indications and Limitations of Coverage and/or Medical Necessity 

Bladder tumor antigen (BTA) is a latex agglutination assay for the qualitative detection of bladder tumor antigen in the urine. The antigen is composed of basement membrane complexes that have been isolated and characterized from the urine of patients with bladder cancer.

Indications:

The BTA test may be used as a method of surveillance for patients with previously diagnosed bladder cancer


Limitations:
The physician must clearly document in the patient’s record that the patient has a history of bladder cancer.

The BTA test is not covered for screening purposes.


 

 

Coverage Topic 

Lab Services
 

 

Coding Information

Bill Type Codes: 

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

12x

Hospital-inpatient or home health visits (Part B only)

13x

Hospital-outpatient (HHA-A also) (under OPPS 13X must be used for ASC claims submitted for OPPS payment -- eff. 7/00)

14x

Non-Patient Laboratory Specimens

 

 

Revenue Codes: 

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory; unless specified in the policy services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

 

030X

Laboratory-general classification

031X

Laboratory pathological-general classification

 

 

CPT/HCPCS Codes 

 

86294

IMMUNOASSAY FOR TUMOR ANTIGEN, QUALITATIVE OR SEMIQUANTITATIVE (EG, BLADDER TUMOR ANTIGEN)

 

 

ICD-9 Codes that Support Medical Necessity 

 

188.0 - 188.9

MALIGNANT NEOPLASM OF TRIGONE OF URINARY BLADDER - MALIGNANT NEOPLASM OF BLADDER PART UNSPECIFIED

198.1

SECONDARY MALIGNANT NEOPLASM OF OTHER URINARY ORGANS

233.7

CARCINOMA IN SITU OF BLADDER

239.4

NEOPLASM OF UNSPECIFIED NATURE OF BLADDER

V10.51

PERSONAL HISTORY OF MALIGNANT NEOPLASM OF BLADDER

 

 

Diagnoses that Support Medical Necessity 

 

 

ICD-9 Codes that DO NOT Support Medical Necessity 

 

 

 

 

ICD-9 Codes that DO NOT Support Medical Necessity Asterisk Explanation 

 

 

Diagnoses that DO NOT Support Medical Necessity 

 

 

General Information

Documentation Requirements 

Documents supporting medical necessity of this test, such as ICD-9 diagnosis code(s), must be submitted with each claim. Claims submitted without such evidence will be denied as being not medically necessary.

The following documents must be made available to Medicare upon request:

 

  • All medical records for services billed
  • Results of laboratory test
  • Itemization of charges

 

 

Appendices 

LINK TO QUESTIONS AND ANSWERS (COMMENTS) ABOUT THIS
POLICY:

Frequently Asked Questions


 

 

Utilization Guidelines 

 

 

Sources of Information and Basis for Decision 

Pathology and Urology Consults

Carrier Medical Directors Clinical Laboratory Workgroup

Other Medical Part B Carriers' Local Medical Review Policies

Medical Tests of Diagnosis 

 

Advisory Committee Meeting Notes 

This policy does not reflect the sole opinion of the contractor or contractor medical director. Although the final decision rests with the contractor, this policy was developed in cooperation with advisory groups, which includes representatives from appropriate specialties as well as provider (facility) representatives. 

 

Start Date of Comment Period 

11/27/1996 

 

End Date of Comment Period 

 

 

Start Date of Notice Period 

12/27/1996 

 

Revision History Number 

068-99h 

 

Revision History Explanation 

01/09/2003 Added 12X to Type of Bill Code

07/24/2002 Formatted

01/25/2002 Updated CPT [2002 Code Book]

02/26/2001 checked ICD-9 & CPT codes with 2001 code books.

08/30/2000 updated for clarification of coverage issues.

This LCD was converted from an LMRP on 12/7/2005

7/2/2006 - The description for Bill code 14 was changed

10/02/2007 - Frequently Asked Questions restored to Appendices. 

 

Reason for Change 

Other
 

Last Reviewed On Date 

10/02/2007 

 

Related Documents 

Article(s)
A37900 - Bladder Tumor Antigen

 

LCD Attachments 

FAQ (869 bytes)

 

Other Versions 

Updated on 09/01/2006 with effective dates 12/08/2005 - N/A

Updated on 07/02/2006 with effective dates 12/08/2005 - N/A

Updated on 12/07/2005 with effective dates 12/08/2005 - N/A

Updated on 12/07/2005 with effective dates 01/09/2003 - 12/07/2005

Updated on 10/13/2003 with effective dates 01/09/2003 - N/A

Updated on 09/16/2003 with effective dates 01/09/2003 - N/A

Updated on 03/11/2003 with effective dates 01/09/2003 - N/A

Updated on 03/07/2003 with effective dates 01/09/2003 - N/A

Updated on 02/15/2003 with effective dates 01/09/2003 - N/A

Updated on 01/08/2003 with effective dates 01/09/2003 - N/A

Updated on 10/04/2002 with effective dates 07/24/2002 - 01/08/2003